Citi raised the firm’s price target on Biogen (BIIB) to $153 from $135 and keeps a Neutral rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $149 from $144 at Morgan Stanley
- Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies
- Stoke, Biogen presents new data from OLE studies of zorevunersen
- Eisai, Biogen announces Leqembi Iqlik availability in the U.S.
- Eisai, Biogen announce U.S. availability of LEQEMBI IQLIK